Evaluation of CYP2C9 Activity
The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9. The purpose of the present study is: 1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity 2. To correlate phenytoin metabolic ratio with CYP2C9 genotype 3. To study the frequency distribution of CYP2C9 activity...
Brief Summary
Official Title: “The Use of Phenytoin Metabolic Ratio as a Putative Marker of CYP2C9 Activity in-Vivo”
The use of phenytoin metabolism to produce S-HPPH accounts for more than 85% of its metabolism. This metabolic pathway is mediated by the activity of CYP2C9.
The purpose of the present study is:
1. To confirm the use of phenytoin metabolic ratio as a marker of CYP2C9 activity
2. To correlate phenytoin metabolic ratio with CYP2C9 genotype
3. To study the frequency distribution of CYP2C9 activity in-vivo
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
Intervention(s) in this Clinical Trial
- Drug: Phenytoin single dose (300 mg)
Outcome Measures for this Clinical Trial
Primary Measures
- Correlation between phenytoin metabolic ratio and CYP2C9 genotype
- Frequency distribution of phenytoin metabolic ratio in the population
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Age range of 20-50 years old
- Absence of significant disease states
Exclusion Criteria:
- The presence of significant disease states
- The use of drugs (including birth control pills)
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 50 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Investigator Information
Lead Investigator: Hadassah Medical Organization Other
Overall Clinical Trial Officials and Contacts
Yoseph Caraco, MD Principal Investigator Hadassah Medical Organization
Overall Contact: Yoseph Caraco, MD 00 972 2 6778584 caraco@hadassah.org.il
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00162461
Study ID Number: yc19559-HMO-CTIL
ClinicalTrials.gov Identifier: NCT00162461
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00162461
